Potential role for angiotensin-converting enzyme inhibitors in the treatment of patients with normal-tension glaucoma

我们研究了坎地沙坦（一种血管紧张素II 1型受体阻滞剂）对青光眼动物模型视网膜神经节细胞（RGCs）神经毒性的神经保护作用。烧灼大鼠的3条巩膜上血管，在一只眼睛中造成慢性和升高的眼内压（IOP）。然后大鼠口服坎地沙坦（1 mg/kg/天）。与对侧对照眼相比，实验期间IOP持续升高约2.5倍。与具有正常IOP的对侧对照眼相比，具有慢性升高IOP的眼的中央视网膜中的RGC存活率在未治疗动物中为46.5%，在坎地沙坦治疗动物中为84.2%。在大鼠慢性青光眼模型中，使用坎地沙坦的连续药理学治疗导致针对RGC损失的显著神经保护。

We investigate the neuroprotective effect of candesartan, an angiotensin II type 1 receptor blocker, against the neurotoxicity of the retinal ganglion cells (RGCs) in an animal model of glaucoma. Cauterization of 3 episcleral vessels in rats was used to create chronically and elevated intraocular pressure (IOP) in one eye. Rats were then orally treated with candesartan (1mg/kg/day). As compared to the contralateral control eyes, there was a consistently elevated IOP of approximately 2.5-fold during the experimental period. As compared to the contralateral control eyes that had normal IOPs, the RGC survival rate in the central retina of eyes with the chronic, elevated IOP was 46.5% in the untreated animals and 84.2% in the candesartan-treated animals. In the rat chronic glaucoma model, continuous pharmacological treatment using candesartan results in significant neuroprotection against RGC loss.